Anti-complement C1s antibodies and methods of inhibiting complement C1s activity

US9562106B2 · kind B2 · utility

Assignee

• True North Therapeutics, Inc. · US

Inventors

• Peter Van Vlasselaer · Sunnyvale, US
• Graham Parry · South San Francisco, US
• Nancy E. Stagliano · South San Francisco, US
• Sandip Panicker · South San Francisco, US

Key dates

• Filing date: Apr 21, 2015
• Grant date: Feb 7, 2017
• Expiry date: Apr 21, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement C1s antibodies inhibit proteolytic activity of C1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.